Targets › SIGMAR1
8 programs from 7 companies in 16 trials: 6 Phase 1, 5 Phase 2, 3 Phase 3, 2 Phase 4; Psychiatry, Neurology, Oncology; next expected readout Dec 2026.
Functions in lipid transport from the endoplasmic reticulum and is involved in a wide array of cellular functions probably through regulation of the biogenesis of lipid microdomains at the plasma membrane. Involved in the regulation of different receptors it plays a role in BDNF signaling and EGF signaling. (UniProt, Q99720)
Open in Phaseline: the race on SIGMAR1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| CSPC Ouyi Pharmaceutical | Dextromethorphan Sigma opioid receptor agonist; Glutamate [NMDA] receptor subunit epsilon 1 antagonist | SIGMAR1, GRIN2A | Phase 3 | Major Depressive Disorder (MDD) | Dec 2026 |
| Zogenix | Fenfluramine Serotonin 1d (5-HT1d) receptor agonist; Serotonin 2c (5-HT2c) receptor agonist; Sigma opioid receptor antagonist | HTR1D, HTR2C, SIGMAR1 | Phase 3 | CDKL5 Deficiency Disorder; Dravet Syndrome (DS); Dravet Syndrome; Infantile Spasm | Nov 2027 |
| UCB BIOSCIENCES | fenfluramine hydrochloride Serotonin 1d (5-HT1d) receptor agonist; Serotonin 2c (5-HT2c) receptor agonist; Sigma opioid receptor antagonist | HTR1D, HTR2C, SIGMAR1 | Phase 3 | Rett Syndrome | Feb 2029 |
| Exciva | Dextromethorphan (EXV-802) Sigma opioid receptor agonist; Glutamate [NMDA] receptor subunit epsilon 1 antagonist | SIGMAR1, GRIN2A | Phase 2 | Agitation Associated With Alzheimer's Disease Dementia; Obsessive-Compulsive Disorder; Hodgkin Lymphoma; Psychedelic Effects in Healthy Volunteers … | Jan 2029 |
| Exciva | EXV-801 Sigma-1 receptor agonist | SIGMAR1 | Phase 2 | Agitation Associated With Alzheimer's Disease Dementia | Jan 2029 |
| Anavex Life Sciences | ANAVEX3-71 Dual SIGMAR1 receptor agonist and M1 positive allosteric modulator | SIGMAR1, CHRM1 | Phase 2 | Schizophrenia | – |
| Pentixapharm | [90Y]Y-PentixaTher Yttrium-90 labelled sigma-1 receptor ligand for endoradiotherapy | SIGMAR1 | Phase 1 | CNS Lymphoma | Sep 2027 |
| Yale University | (S)-[18F]FBFP Sigma-1 receptor radiotracer | SIGMAR1 | Phase 1 | Healthy Control Subjects | May 2028 |
Agitation Associated With Alzheimer's Disease Dementia (2) Healthy Control Subjects (2) Rett Syndrome (1) Schizophrenia (1) CNS Lymphoma (1) Obsessive-Compulsive Disorder (1) Hodgkin Lymphoma (1) Psychedelic Effects in Healthy Volunteers (1) Major Depression (1) CDKL5 Deficiency Disorder (1) Dravet Syndrome (DS) (1) Dravet Syndrome (1)
small molecule (7), protein or peptide (1)
Exciva (2) UCB BIOSCIENCES (1) Anavex Life Sciences (1) Pentixapharm (1) Yale University (1) Zogenix (1) CSPC Ouyi Pharmaceutical (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.